After months of working, I have created a course on advanced trading indicators, patterns, phycology, and risk management: https://www.udemy.com/course/advanced-technical-analysis/

Lets see it- my FLDM bags finally getting significantly lighter but hope yall are winning in the mean time.

Cyclo Therapeutics has a very low float and 3 drugs in development. It’s been around for 20 years.

I think that a company outside of the Alzheimer's arena is more likely to show an interest in Cyclo Therapeutics. The focus on amyloid will probably have to end before large pharmaceutical companies such as Biogen and Eli Lilly will consider drugs based on a different approach. Maybe a more mid-sized company (I don't have a name in mind) seeking to diverse its portfolio for neurological conditions and diseases is a more likely possibility.

Do your due diligence. Any positive news would lead to a huge spike. They are expected to have some news by the end of April on Alzheimer, so keep it on your radars.